CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: PHAX (ImmuneEditome ID:51808)

1. Gene summary of enriched editing regions for PHAX

check button Gene summary
Gene informationGene symbol

PHAX

Gene ID

51808

GeneSynonymsRNUXA
GeneCytomap

5q23.2

GeneTypeprotein-coding
GeneDescriptionphosphorylated adapter RNA export protein|RNA U small nuclear RNA export adapter protein|RNA U, small nuclear RNA export adapter (phosphorylation regulated)|RNA U, small nuclear RNA export adaptor (phosphorylation regulated)
GeneModificationdate20230329
UniprotIDQ9H814
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr5:126625284-126626885:+ENST00000513813.1ENSG00000164902.12PHAXncRNA_exonicAluSz6,FLAM_C,AluSc,AluSzchr5:126625284-126626885:+.alignment


Top

2. Tumor-specific enriched editing regions for PHAX


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr5:126625284-126626885:+BRCAEER6.9197e-15image
ENSG00000164902.12,PHAXBRCAEAG5.8977e-15image
chr5:126625284-126626885:+COADEER2.8562e-12image
ENSG00000164902.12,PHAXCOADEAG1.4250e-12image
chr5:126625284-126626885:+HNSCEER3.3376e-10image
ENSG00000164902.12,PHAXHNSCEAG3.3376e-10image
chr5:126625284-126626885:+KICHEER4.9341e-02image
ENSG00000164902.12,PHAXKICHEAG4.9341e-02image
chr5:126625284-126626885:+KIRPEER3.2247e-04image
ENSG00000164902.12,PHAXKIRPEAG3.2247e-04image
chr5:126625284-126626885:+LIHCEER4.3636e-03image
ENSG00000164902.12,PHAXLIHCEAG4.3636e-03image
chr5:126625284-126626885:+LUSCEER1.3148e-06image
ENSG00000164902.12,PHAXLUSCEAG1.3148e-06image
chr5:126625284-126626885:+PRADEER6.3650e-03image
ENSG00000164902.12,PHAXPRADEAG6.2617e-03image
chr5:126625284-126626885:+THCAEER1.2182e-02image
ENSG00000164902.12,PHAXTHCAEAG1.2182e-02image
chr5:126625284-126626885:+UCECEER9.9285e-11image
ENSG00000164902.12,PHAXUCECEAG9.9285e-11image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr5:126625284-126626885:+CESCCliEER2.0191e-029.4854e-03-0.1508image
ENSG00000164902.12,PHAXCESCCliEAG2.0191e-029.4854e-03-0.1508image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr5:126625284-126626885:+LAMLEER2.9875e-023.7831e-023.8495e+01image
ENSG00000164902.12,PHAXLAMLEAG2.9875e-023.7831e-023.8495e+01image

Top

3. Enriched editing regions and immune related genes for PHAX


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr5:126625284-126626885:+COADEERENSG00000073050,XRCC1-0.31376.3006e-059.8158e-12-0.4010imageNFUS;IGF2BP2XRCC1EosinophilsGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
chr5:126625284-126626885:+COADEERENSG00000180596,HIST1H2BC0.26751.0425e-032.2336e-310.6336imageNFUS;IGF2BP2;QKINAT_cells_CD4_memory_restingGSVA_HALLMARK_UV_RESPONSE_UP
chr5:126625284-126626885:+COADEERENSG00000198055,GRK6-0.26391.3988e-032.7404e-12-0.4107imageNFUS;IGF2BP2;QKINAEosinophilsGSVA_HALLMARK_DNA_REPAIR
chr5:126625284-126626885:+COADEERENSG00000277918,U10.15631.5073e-036.8943e-390.6888imageNNNAMast_cells_activatedGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr5:126625284-126626885:+COADEERENSG00000162695,SLC30A70.25062.1533e-031.1696e-190.5171imageNFUS;IGF2BP2;QKINAEosinophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr5:126625284-126626885:+COADEERENSG00000072415,MPP50.25282.3069e-031.1906e-120.4169imageNFUS;IGF2BP2;QKINAEosinophilsGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr5:126625284-126626885:+COADEERENSG00000029364,SLC39A90.25172.5146e-032.4822e-120.4114imageNFUS;IGF2BP2;QKINAEosinophilsGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr5:126625284-126626885:+COADEERENSG00000169905,TOR1AIP20.24733.0690e-033.8126e-220.5460imageNFUS;IGF2BP2;QKINAEosinophilsGSVA_HALLMARK_XENOBIOTIC_METABOLISM
chr5:126625284-126626885:+COADEERENSG00000156735,BAG40.23863.6886e-035.1366e-150.4545imageNFUS;IGF2BP2;QKIBAG4NeutrophilsGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
chr5:126625284-126626885:+COADEERENSG00000198252,STYX0.24223.7079e-036.9393e-180.4947imageNFUS;IGF2BP2;QKINAEosinophilsGSVA_HALLMARK_P53_PATHWAY

More results



Top

4. Enriched editing regions and immune related splicing for PHAX


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000164902.12,PHAX
COADEAGMEXENSG00000176953.6chr1628954605:28954682:28955977:28956337:28958990:28959100:28963704:289642790.21984.8083e-024.9506e-130.4233imageNACIN1;ADAR;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM47;RNF219;SAFB2;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZC3H7B;ZNF184NFATC2IPNeutrophilsGSVA_HALLMARK_ANDROGEN_RESPONSE
ENSG00000164902.12,PHAX
COADEAGESENSG00000168827.10chr3158684630:158684668:158690162:158690323:158691138:158691192-0.19124.1806e-021.2332e-35-0.6672imageNACIN1;ADAR;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM47;RNF219;SAFB2;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZC3H7B;ZNF184NANK_cells_activatedGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
chr5:126625284-126626885:+
COADEERA5ENSG00000026508.12chr1135198120:35198246:35189834:35190065:35189834:35196874-0.27131.4702e-039.4345e-12-0.4114imageNFUS;IGF2BP2CD44Dendritic_cells_activatedGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
chr5:126625284-126626885:+
COADEERESENSG00000168827.10chr3158684630:158684668:158690162:158690323:158691138:158691192-0.19892.4779e-028.5778e-37-0.6754imageNFUS;IGF2BP2;QKINANK_cells_activatedGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
ENSG00000164902.12,PHAX
COADEAGESENSG00000176731.7chr885214555:85214631:85214920:85215037:85217385:85217502-0.23502.7797e-023.5839e-17-0.4852imageNACIN1;ADAR;AUH;BCCIP;BUD13;CELF2;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MOV10;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RNF219;SAFB2;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;ZNF184NANK_cells_restingGSVA_HALLMARK_BILE_ACID_METABOLISM
chr5:126625284-126626885:+
COADEERMEXENSG00000176953.6chr1628954605:28954682:28955977:28956337:28958990:28959100:28963704:289642790.22024.2060e-023.7286e-120.4084imageNFUS;IGF2BP2;QKINFATC2IPNeutrophilsGSVA_HALLMARK_ANDROGEN_RESPONSE
ENSG00000164902.12,PHAX
COADEAGMEXENSG00000164941.9chr894867172:94867196:94867275:94867337:94871890:94872002:94873373:948734770.26048.2633e-034.3755e-230.5562imageNACIN1;ADAR;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RNF219;SAFB2;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;ZNF184NAT_cells_CD4_memory_restingGSVA_HALLMARK_DNA_REPAIR
ENSG00000164902.12,PHAX
COADEAGESENSG00000114416.13chr3180970266:180970358:180975312:180975404:180976121:180976282-0.28271.7444e-038.6678e-15-0.4511imageNACIN1;ADAR;AUH;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM47;SAFB2;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZC3H7B;ZNF184FXR1Mast_cells_activatedGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE
ENSG00000164902.12,PHAX
COADEAGIRENSG00000058673.11chr1203795659:203795794:203801574:2038022610.22621.3259e-022.3165e-180.5422imageNACIN1;ADAR;AUH;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM47;RNF219;SAFB2;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZC3H7B;ZNF184NAEosinophilsGSVA_HALLMARK_PEROXISOME
chr5:126625284-126626885:+
COADEERMEXENSG00000164941.9chr894867172:94867196:94867275:94867337:94871890:94872002:94873373:948734770.25957.2528e-032.8600e-120.4104imageNFUS;IGF2BP2;QKINAT_cells_CD4_memory_restingGSVA_HALLMARK_DNA_REPAIR

More results



Top

5. Enriched editing regions and immune infiltration for PHAX


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr5:126625284-126626885:+BLCAEERMacrophages_M12.8960e-030.1501image
ENSG00000164902.12,PHAXBLCAEAGMacrophages_M12.8864e-030.1499image
chr5:126625284-126626885:+BRCAEERMacrophages_M19.4788e-050.1189image
ENSG00000164902.12,PHAXBRCAEAGMacrophages_M11.3934e-040.1160image
chr5:126625284-126626885:+CESCEERB_cells_naive2.2967e-02-0.1313image
ENSG00000164902.12,PHAXCESCEAGB_cells_naive2.2967e-02-0.1313image
chr5:126625284-126626885:+CHOLEERNK_cells_resting1.1746e-02-0.4212image
ENSG00000164902.12,PHAXCHOLEAGNK_cells_resting1.1746e-02-0.4212image
chr5:126625284-126626885:+COADEERDendritic_cells_activated2.3423e-040.2233image
ENSG00000164902.12,PHAXCOADEAGDendritic_cells_activated2.9911e-070.3074image
chr5:126625284-126626885:+DLBCEERNK_cells_activated1.0750e-020.3688image
ENSG00000164902.12,PHAXDLBCEAGNK_cells_activated1.0799e-020.3686image
chr5:126625284-126626885:+ESCAEERT_cells_follicular_helper1.4131e-02-0.1937image
ENSG00000164902.12,PHAXESCAEAGT_cells_follicular_helper1.4884e-02-0.1922image
chr5:126625284-126626885:+GBMEERMacrophages_M06.0053e-05-0.3062image
ENSG00000164902.12,PHAXGBMEAGMacrophages_M06.0053e-05-0.3062image
chr5:126625284-126626885:+HNSCEERT_cells_follicular_helper7.7382e-03-0.1208image
ENSG00000164902.12,PHAXHNSCEAGT_cells_follicular_helper7.7382e-03-0.1208image
chr5:126625284-126626885:+KIRCEERPlasma_cells3.2600e-020.1095image
ENSG00000164902.12,PHAXKIRCEAGPlasma_cells3.2600e-020.1095image
chr5:126625284-126626885:+KIRPEERB_cells_memory4.4768e-040.2106image
ENSG00000164902.12,PHAXKIRPEAGB_cells_memory4.4768e-040.2106image
chr5:126625284-126626885:+LGGEERMacrophages_M12.2905e-020.0989image
ENSG00000164902.12,PHAXLGGEAGMacrophages_M12.2905e-020.0989image
chr5:126625284-126626885:+LIHCEERMacrophages_M13.7746e-020.1090image
ENSG00000164902.12,PHAXLIHCEAGMacrophages_M13.7746e-020.1090image
chr5:126625284-126626885:+LUADEERDendritic_cells_resting4.1698e-04-0.1566image
ENSG00000164902.12,PHAXLUADEAGDendritic_cells_resting4.2852e-04-0.1563image
chr5:126625284-126626885:+LUSCEERT_cells_CD4_memory_resting7.5592e-04-0.1518image
ENSG00000164902.12,PHAXLUSCEAGT_cells_CD4_memory_resting7.5592e-04-0.1518image
chr5:126625284-126626885:+OVEERT_cells_follicular_helper2.6334e-020.1304image
ENSG00000164902.12,PHAXOVEAGT_cells_follicular_helper2.4666e-020.1319image
chr5:126625284-126626885:+PAADEERMacrophages_M01.9156e-020.1764image
ENSG00000164902.12,PHAXPAADEAGMacrophages_M01.9156e-020.1764image
chr5:126625284-126626885:+PCPGEERT_cells_CD81.9237e-020.1753image
ENSG00000164902.12,PHAXPCPGEAGT_cells_CD81.9237e-020.1753image
chr5:126625284-126626885:+PRADEERT_cells_regulatory_(Tregs)6.0469e-050.1794image
ENSG00000164902.12,PHAXPRADEAGT_cells_regulatory_(Tregs)6.2480e-050.1791image
chr5:126625284-126626885:+READEERT_cells_CD83.3789e-020.2192image
ENSG00000164902.12,PHAXREADEAGT_cells_CD83.3789e-020.2192image
chr5:126625284-126626885:+SARCEERT_cells_CD4_naive1.0950e-02-0.1588image
ENSG00000164902.12,PHAXSARCEAGT_cells_CD4_naive1.0950e-02-0.1588image
chr5:126625284-126626885:+SKCMEERT_cells_CD87.6832e-060.2101image
ENSG00000164902.12,PHAXSKCMEAGT_cells_CD87.6832e-060.2101image
chr5:126625284-126626885:+STADEERT_cells_CD4_memory_resting1.0682e-03-0.1720image
ENSG00000164902.12,PHAXSTADEAGT_cells_CD4_memory_resting1.0634e-03-0.1721image
chr5:126625284-126626885:+TGCTEERNeutrophils2.6460e-050.3359image
ENSG00000164902.12,PHAXTGCTEAGNeutrophils2.6460e-050.3359image
chr5:126625284-126626885:+THCAEERT_cells_regulatory_(Tregs)1.3547e-030.1428image
ENSG00000164902.12,PHAXTHCAEAGT_cells_regulatory_(Tregs)1.3547e-030.1428image
chr5:126625284-126626885:+THYMEERMacrophages_M11.2469e-030.3000image
ENSG00000164902.12,PHAXTHYMEAGMacrophages_M11.2469e-030.3000image
chr5:126625284-126626885:+UCSEEREosinophils3.7363e-02-0.2815image
ENSG00000164902.12,PHAXUCSEAGEosinophils3.7363e-02-0.2815image
chr5:126625284-126626885:+UVMEEREosinophils3.1483e-020.3016image
ENSG00000164902.12,PHAXUVMEAGEosinophils3.1483e-020.3016image


Top

6. Enriched editing regions and immune gene sets for PHAX


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot
chr5:126625284-126626885:+KIRPEER1.8127e-02image3.1271e-02-0.1301image
ENSG00000164902.12,PHAXKIRPEAG1.8127e-02image3.1271e-02-0.1301image


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
ENSG00000164902.12,PHAXCOADEAG3.1902e-03-0.17982.7149e-02-0.13521.0544e-03-0.19944.6938e-02-0.1217image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr5:126625284-126626885:+BLCAGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER4.1632e-040.1774image
ENSG00000164902.12,PHAXBLCAGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG4.2634e-040.1769image
ENSG00000164902.12,PHAXBRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.8705e-180.2630image
chr5:126625284-126626885:+BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER4.7779e-190.2676image
chr5:126625284-126626885:+CESCGSVA_HALLMARK_COMPLEMENTEER1.0072e-030.1889image
ENSG00000164902.12,PHAXCESCGSVA_HALLMARK_COMPLEMENTEAG1.0072e-030.1889image
ENSG00000164902.12,PHAXCHOLGSVA_HALLMARK_COAGULATIONEAG3.1110e-02-0.3650image
chr5:126625284-126626885:+CHOLGSVA_HALLMARK_COAGULATIONEER3.1110e-02-0.3650image
ENSG00000164902.12,PHAXCOADGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG1.5531e-06-0.2891image
chr5:126625284-126626885:+COADGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER1.1042e-05-0.2654image
chr5:126625284-126626885:+DLBCGSVA_HALLMARK_MITOTIC_SPINDLEEER2.1578e-03-0.4365image
ENSG00000164902.12,PHAXDLBCGSVA_HALLMARK_MITOTIC_SPINDLEEAG2.1528e-03-0.4366image
ENSG00000164902.12,PHAXESCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.0723e-030.2563image
chr5:126625284-126626885:+ESCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.1552e-030.2547image
ENSG00000164902.12,PHAXGBMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.6428e-090.4465image
chr5:126625284-126626885:+GBMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.6428e-090.4465image
ENSG00000164902.12,PHAXHNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG4.4400e-030.1290image
chr5:126625284-126626885:+HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER4.4400e-030.1290image
chr5:126625284-126626885:+KICHGSVA_HALLMARK_UV_RESPONSE_UPEER1.4263e-020.3027image
ENSG00000164902.12,PHAXKICHGSVA_HALLMARK_UV_RESPONSE_UPEAG1.4263e-020.3027image
ENSG00000164902.12,PHAXKIRCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.6510e-020.1228image
chr5:126625284-126626885:+KIRCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.6510e-020.1228image
ENSG00000164902.12,PHAXKIRPGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.6654e-06-0.2847image
chr5:126625284-126626885:+KIRPGSVA_HALLMARK_PROTEIN_SECRETIONEER1.6654e-06-0.2847image
chr5:126625284-126626885:+LGGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.5157e-060.2073image
ENSG00000164902.12,PHAXLGGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.5157e-060.2073image
chr5:126625284-126626885:+LIHCGSVA_HALLMARK_BILE_ACID_METABOLISMEER5.5134e-070.2589image
ENSG00000164902.12,PHAXLIHCGSVA_HALLMARK_BILE_ACID_METABOLISMEAG5.5134e-070.2589image
ENSG00000164902.12,PHAXLUADGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG2.9659e-03-0.1321image
chr5:126625284-126626885:+LUADGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER2.7933e-03-0.1329image
chr5:126625284-126626885:+LUSCGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER4.7380e-05-0.1829image
ENSG00000164902.12,PHAXLUSCGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG4.7380e-05-0.1829image
ENSG00000164902.12,PHAXMESOGSVA_HALLMARK_SPERMATOGENESISEAG3.0224e-02-0.2410image
chr5:126625284-126626885:+MESOGSVA_HALLMARK_SPERMATOGENESISEER3.0224e-02-0.2410image
ENSG00000164902.12,PHAXOVGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.0121e-040.2263image
chr5:126625284-126626885:+OVGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER7.5049e-050.2304image
chr5:126625284-126626885:+PAADGSVA_HALLMARK_SPERMATOGENESISEER2.8548e-02-0.1651image
ENSG00000164902.12,PHAXPAADGSVA_HALLMARK_SPERMATOGENESISEAG2.8548e-02-0.1651image
ENSG00000164902.12,PHAXPCPGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG9.1187e-040.2465image
chr5:126625284-126626885:+PCPGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER9.1187e-040.2465image
ENSG00000164902.12,PHAXPRADGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG1.4753e-03-0.1427image
chr5:126625284-126626885:+PRADGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER1.5439e-03-0.1421image
chr5:126625284-126626885:+READGSVA_HALLMARK_ANDROGEN_RESPONSEEER1.9364e-03-0.3157image
ENSG00000164902.12,PHAXREADGSVA_HALLMARK_ANDROGEN_RESPONSEEAG1.9364e-03-0.3157image
ENSG00000164902.12,PHAXSARCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG4.0833e-050.2535image
chr5:126625284-126626885:+SARCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER4.0833e-050.2535image
ENSG00000164902.12,PHAXSKCMGSVA_HALLMARK_MYOGENESISEAG6.8167e-060.2112image
chr5:126625284-126626885:+SKCMGSVA_HALLMARK_MYOGENESISEER6.8167e-060.2112image
ENSG00000164902.12,PHAXSTADGSVA_HALLMARK_UV_RESPONSE_UPEAG9.5855e-060.2312image
chr5:126625284-126626885:+STADGSVA_HALLMARK_UV_RESPONSE_UPEER7.5263e-060.2339image
ENSG00000164902.12,PHAXTGCTGSVA_HALLMARK_GLYCOLYSISEAG2.4765e-04-0.2950image
chr5:126625284-126626885:+TGCTGSVA_HALLMARK_GLYCOLYSISEER2.4765e-04-0.2950image
chr5:126625284-126626885:+THCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER5.2478e-040.1544image
ENSG00000164902.12,PHAXTHCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG5.2478e-040.1544image
ENSG00000164902.12,PHAXTHYMGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG3.8853e-030.2696image
chr5:126625284-126626885:+THYMGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER3.8853e-030.2696image
chr5:126625284-126626885:+UCECGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER7.9836e-030.2034image
ENSG00000164902.12,PHAXUCECGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG7.9836e-030.2034image
ENSG00000164902.12,PHAXUCSGSVA_HALLMARK_E2F_TARGETSEAG3.4590e-020.2855image
chr5:126625284-126626885:+UCSGSVA_HALLMARK_E2F_TARGETSEER3.4590e-020.2855image
chr5:126625284-126626885:+UVMGSVA_HALLMARK_APICAL_SURFACEEER1.1960e-020.3494image
ENSG00000164902.12,PHAXUVMGSVA_HALLMARK_APICAL_SURFACEEAG1.1960e-020.3494image


Top

7. Enriched editing regions and drugs for PHAX


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000164902.12,PHAXBLCAFH535EAG4.4178e-050.2045image
chr5:126625284-126626885:+BLCAFH535EER4.5187e-050.2045image
chr5:126625284-126626885:+BRCAAxitinibEER7.5953e-050.1206image
ENSG00000164902.12,PHAXBRCAAxitinibEAG4.9595e-050.1235image
ENSG00000164902.12,PHAXCESCAZD6244EAG5.4707e-06-0.2590image
chr5:126625284-126626885:+CESCAZD6244EER5.4707e-06-0.2590image
ENSG00000164902.12,PHAXCOADAZ628EAG2.1088e-120.4127image
chr5:126625284-126626885:+COADAZ628EER8.0018e-100.3647image
chr5:126625284-126626885:+DLBCAZ628EER4.0350e-04-0.4951image
ENSG00000164902.12,PHAXDLBCAZ628EAG4.0325e-04-0.4951image
ENSG00000164902.12,PHAXESCAEHT.1864EAG7.8706e-030.2094image
chr5:126625284-126626885:+ESCAEHT.1864EER6.9013e-030.2128image
chr5:126625284-126626885:+GBMBIBW2992EER4.2018e-10-0.4607image
ENSG00000164902.12,PHAXGBMBIBW2992EAG4.2018e-10-0.4607image
ENSG00000164902.12,PHAXHNSCFH535EAG8.0615e-050.1781image
chr5:126625284-126626885:+HNSCFH535EER8.0615e-050.1781image
chr5:126625284-126626885:+KICHGefitinibEER4.9863e-030.3442image
ENSG00000164902.12,PHAXKICHGefitinibEAG4.9863e-030.3442image
chr5:126625284-126626885:+KIRCBexaroteneEER7.1753e-060.2277image
ENSG00000164902.12,PHAXKIRCBexaroteneEAG7.1753e-060.2277image
ENSG00000164902.12,PHAXKIRPAZD6244EAG1.0061e-04-0.2328image
chr5:126625284-126626885:+KIRPAZD6244EER1.0061e-04-0.2328image
ENSG00000164902.12,PHAXLGGLapatinibEAG1.3202e-04-0.1654image
chr5:126625284-126626885:+LGGLapatinibEER1.3202e-04-0.1654image
chr5:126625284-126626885:+LIHCAZD.2281EER9.7593e-040.1740image
ENSG00000164902.12,PHAXLIHCAZD.2281EAG9.7593e-040.1740image
chr5:126625284-126626885:+LUADFH535EER1.4906e-030.1411image
ENSG00000164902.12,PHAXLUADFH535EAG1.4578e-030.1414image
chr5:126625284-126626885:+LUSCCCT018159EER5.7826e-05-0.1808image
ENSG00000164902.12,PHAXLUSCCCT018159EAG5.7826e-05-0.1808image
ENSG00000164902.12,PHAXMESODasatinibEAG2.4517e-02-0.2498image
chr5:126625284-126626885:+MESODasatinibEER2.4517e-02-0.2498image
ENSG00000164902.12,PHAXOVBI.D1870EAG7.2666e-050.2308image
chr5:126625284-126626885:+OVBI.D1870EER9.1271e-050.2277image
ENSG00000164902.12,PHAXPAADGW843682XEAG7.3700e-04-0.2521image
chr5:126625284-126626885:+PAADGW843682XEER7.3700e-04-0.2521image
ENSG00000164902.12,PHAXPCPGLapatinibEAG3.2562e-06-0.3407image
chr5:126625284-126626885:+PCPGLapatinibEER3.2562e-06-0.3407image
ENSG00000164902.12,PHAXPRADBicalutamideEAG6.7550e-040.1524image
chr5:126625284-126626885:+PRADBicalutamideEER7.4869e-040.1512image
ENSG00000164902.12,PHAXREADBicalutamideEAG2.7718e-030.3053image
chr5:126625284-126626885:+READBicalutamideEER2.7718e-030.3053image
ENSG00000164902.12,PHAXSARCFTI.277EAG9.9698e-060.2722image
chr5:126625284-126626885:+SARCFTI.277EER9.9698e-060.2722image
ENSG00000164902.12,PHAXSKCMGNF.2EAG3.8479e-10-0.2908image
chr5:126625284-126626885:+SKCMGNF.2EER3.8479e-10-0.2908image
ENSG00000164902.12,PHAXSTADBMS.708163EAG8.8761e-040.1747image
chr5:126625284-126626885:+STADBMS.708163EER9.0836e-040.1744image
ENSG00000164902.12,PHAXTGCTAZD6244EAG1.1898e-05-0.3492image
chr5:126625284-126626885:+TGCTAZD6244EER1.1898e-05-0.3492image
chr5:126625284-126626885:+THCAAG.014699EER1.0196e-070.2351image
ENSG00000164902.12,PHAXTHCAAG.014699EAG1.0196e-070.2351image
chr5:126625284-126626885:+THYMDoxorubicinEER1.0974e-030.3032image
ENSG00000164902.12,PHAXTHYMDoxorubicinEAG1.0974e-030.3032image
chr5:126625284-126626885:+UCECA.770041EER2.7516e-13-0.5237image
ENSG00000164902.12,PHAXUCECA.770041EAG2.7516e-13-0.5237image
ENSG00000164902.12,PHAXUCSAZD7762EAG1.6665e-03-0.4142image
chr5:126625284-126626885:+UCSAZD7762EER1.6665e-03-0.4142image
chr5:126625284-126626885:+UVMBMS.708163EER1.2902e-030.4384image
ENSG00000164902.12,PHAXUVMBMS.708163EAG1.2902e-030.4384image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType